Meine Profile

Nach meinem Studium der Informatik mit Schwerpunkt Computer Graphics und Medizininformatik war ich von 2001 bis 2007 an der Charite Berlin an den Standorten Virchow Klinikum, Mitte und Buch tätig. Danach wechselte ich vom wissenschaftlichen Mitarbeiter zur MagForce Nanotechnologies AG, wo ich an dem Entwicklungsprojekt zur Software NanoPlan nahezu 3 Jahre leitend mitwirkte...
Meinen Ausflug als Freiberufler habe ich dann 2012 gegen meine Stelle bei der PSI AG (Software für Gas & Öl-Anwendungen) eingetauscht. Aktuell bin ich auf der Suche nach einer interessanteren Tätigkeit mit z.B. Qt5, VTK ...
Meine Schwerpunkte liegen im Bereich C++, Computer Graphics, MedIT, Usability Engineering, Design und Kreativität!

Mein aktuelles Profil Dezember 2014

Mein aktuelles Profil...

Mein Profil als PDF(Stand: Dezember 2014):

Aktuelles PDF, 15 Seiten:

BEWERBUNG_REHBEIN_2014-12-01.pdf

Vorheriges Profil

Mein Profil als PDF und PPT (Stand: Januar 2013):

Aktuelles PDF, 15 Seiten:

Profil_Dipl_Inf_Hagen_Rehbein_2013-01-15.pdf

PowerPoint, 15 Seiten:

Profil_Dipl_Inf_Hagen_Rehbein_2013-01-15.ppt

PDF, doppelseitig, SW, 8 Seiten:

Profil_Dipl_Inf_Hagen_Rehbein_2013-01-15-BW_2Pages.pdf


Frühere wissenschaftliche Projekte als wissenschaftlicher Mitarbeiter

Prostata-Projekt 2005 bis 2006:

Radiology. 2009 Jul;252(1):101-108.

Prostate MR imaging: Tissue Characterization with Pharmacokinetic Volume and Blood Flow Parameters and Correlation with Histologic Parameters.

[Franiel T (MD), Lüdemann L (MS, PhD), Rudolph B (MD), Rehbein H (MS), Stephan C (MD), Taupitz M (MS,MS,PhD), Beyersdorff D (MD,PhD).

SourceDepartment of Radiology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. tobias.franiel@charite.de]

PURPOSE: To prospectively determine whether pharmacokinetic magnetic resonance (MR) imaging parameters correlate with histologic mean vessel density (MVD), mean vessel area (MVA), and mean interstitial area (MIA) and whether these parameters enable differentiation of prostate cancer, chronic prostatitis, and normal prostate tissue.

(c) RSNA, 2009. PMID:19561252[PubMed - indexed for MEDLINE]

Radiology. 2009 Jul;252(1):101-108.

Prostate MR imaging: Tissue Characterization with Pharmacokinetic Volume and Blood Flow Parameters and Correlation with Histologic Parameters.

[Franiel T (MD), Lüdemann L (MS, PhD), Rudolph B (MD), Rehbein H (MS), Stephan C (MD), Taupitz M (MS,MS,PhD), Beyersdorff D (MD,PhD).

SourceDepartment of Radiology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. tobias.franiel@charite.de]

PURPOSE: To prospectively determine whether pharmacokinetic magnetic resonance (MR) imaging parameters correlate with histologic mean vessel density (MVD), mean vessel area (MVA), and mean interstitial area (MIA) and whether these parameters enable differentiation of prostate cancer, chronic prostatitis, and normal prostate tissue.

(c) RSNA, 2009. PMID:19561252[PubMed - indexed for MEDLINE]

Ann Biomed Eng. 2009 Apr;37(4):749-762. Epub 2009 Jan 24.

Simultaneous quantification of perfusion and permeability in the prostate using dynamic contrast-enhanced magnetic resonance imaging with an inversion-prepared dual-contrast sequence.

[Lüdemann L, Prochnow D, Rohlfing T, Franiel T, Warmuth C, Taupitz M, Rehbein H, Beyersdorff D. SourceDepartment of Radiotherapy, Charité-Universitätsmedizin Berlin, Charité Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. lutz.luedemann@charite.de]
Abstract:
The aim of the present study was to quantify both perfusion and extravasation in the prostate to discriminate tumor from healthy tissue, which might be achieved by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using a nonspecific low-molecular-weight contrast medium (CM). To determine extravasation as well as tissue perfusion an inversion-prepared dual-contrast sequence employing a parallel acquisition technique (PAT) was designed for interleaved acquisition of T(1)-weighted images for extravasation measurement and T(2)*-weighted images for determination of the highly concentrated bolus with a sufficiently high temporal and spatial resolution at an acceptable signal-to-noise ratio. Thirteen patients with proven prostate cancer were examined with the sequence using a combined body-array prostate coil. Before pharmacokinetic evaluation the images were intensity-corrected and, if required, motion-corrected. The pharmacokinetic model used to calculate perfusion, permeability, blood volume, interstitial volume, transit time, and vessel size index included two compartments and a correction of delay and dispersion of the arterial input function. The information provided by the dual-contrast sequence allowed application of a more elaborate model for evaluation and enabled quantification of all parameters. Peripheral prostate tumors were found to differ from peripheral healthy prostate tissue in perfusion (1.38 mL/(min cm(3)) vs. 0.23 mL/(min cm(3)), p=0.004), mean transit time (2.88 vs. 4.88 s, p=0.039), and blood volume (1.9 vs. 0.7%, p=0.019). A inversion-prepared dual-contrast sequence acquiring T(1)- and T*(2)-weighted images with sufficient temporal resolution and signal-to-noise ratio was successfully applied in patients with prostate cancer to quantify all pharmacokinetic parameters of inflow and extravasation of a low-molecular-weight inert tracer.

PMID:19169821[PubMed - indexed for MEDLINE]

Proc. Intl. Soc. Mag. Reson. Med. 17 (2009)

Delay and dispersion correction for simultaneous quantification of perfusion and permeability in the prostate using DCE-MRI with a dual-contrast sequence

[L. Lüdemann1, T. Franiel2, M. Taupitz2, H. Rehbein1, and D. Beyersdorff2 1Department of Radiotherapy, CVK, Charité, Berlin, Berlin, Germany, 2Department of Radiology, Charité, Berlin, Berlin, Germany]

Invest Radiol. 2008 Jul;43(7):481-487.

Evaluation of normal prostate tissue, chronic prostatitis, and prostate cancer by quantitative perfusion analysis using a dynamic contrast-enhanced inversion-prepared dual-contrast gradient echo sequence.

[Franiel T, Lüdemann L, Rudolph B, Rehbein H, Staack A, Taupitz M, Prochnow D, Beyersdorff D. SourceDepartments of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany. tobias.franiel@charite.de]
Abstract:
OBJECTIVE: To quantify independent pharmacokinetic parameters for differentiation of prostate pathology.

PMID:18580330[PubMed - indexed for MEDLINE]

Proc. Intl. Soc. Mag. Reson. Med. 14 (2006).

Quantification of proton exchange by histological verification of fractional blood volume determined by an intravascular T1 contrast agent at prostate tissue and prostate tumor

[L. Lüdemann1, O. Gemeinhardt2, G. Correia Carreira2, H. Rehbein1, C. Warmuth2, M. Taupitz2, D. Beyersdorff2 1Department of Radiooncology, Charité, Berlin, Berlin, Germany, 2Department of Radiology, Charité, Berlin, Berlin, Germany]

Schweinenieren-Projekt 2006:

Invest Radiol. 2009 Mar;44(3):125-134.

Absolute quantification of regional renal blood flow in swine by dynamic contrast-enhanced magnetic resonance imaging using a blood pool contrast agent.

[Lüdemann L, Nafz B, Elsner F, Grosse-Siestrup C, Meissler M, Kaufels N, Rehbein H, Persson PB, Michaely HJ, Lengsfeld P, Voth M, Gutberlet M. SourceDepartment of Radiotherapy, Charité, Berlin, Germany. lutz.luedemann@charite.de]
Abstract: AIM: To evaluate for the first time in an animal model the possibility of absolute regional quantification of renal medullary and cortical perfusion by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using a blood pool contrast agent.

PMID:19151609[PubMed - indexed for MEDLINE]

39. DGMP Tagung 2008 in Oldenburg [Schweinenieren-Projekt 2006]

Validierung der Nierenperfusionsmessung mittels DCE-MRI mit einem intravasalen Kontrastmittel an einem Schweinemodell

[Lutz Lüdemann, Benno Nafz, Franz Elsner, Michael Meissler, Nicola Kaufels, Hagen Rehbein, Philipp Lengsfeld, Christian Große-Stiestrup, Pontus Persson, Matthias Voth, Matthias Gutberlet Klinik für Strahlenheilkunde, Charité, Campus Virchow-Klinikum, Berlin]

BMBF-Panik Projekt 2006 bis 2007:

Eur Arch Psychiatry Clin Neurosci. 2011 Apr;261(3):185-94. Epub 2010 Nov 27.

The Westphal paradigm: A new paradigm to study the neuronal correlates of agoraphobia.

[Wittmann A, Schlagenhauf F, John T, Guhn A, Rehbein H, Siegmund A, Stoy M, Held D, Schulz I, Fehm L, Fydrich T, Heinz A, Bruhn H, Ströhle A.]

PMID:21113608[PubMed - indexed for MEDLINE]

Änderungen der durch störungsspezifische Stimuli induzierten funktionellen Aktivierungsmuster bei Patienten mit Agoraphobie und Panikstörung vor und nach CBT.

[A Wittmann, A Guhn, F Schlagenhauf, T Fydrich, A Siegmund, M Stoy, B Pfleiderer, U Lueken, H Bruhn, H Rehbein, L Fehm, C Konrad, T Kircher, I Reinhardt, H Wittchen und A Ströhle]

Poster, European Archives of Psychiatry and Clinical Neuroscience, 260 (S1).

Modulation of functional activation patterns by disorder-specific stimuli before and after CBT in patients with agoraphobia and panic disorder.

[Wittmann, A., Guhn, A., Schlagenhauf, F., Fydrich, T., Siegmund, A., Stoy, M., Pfleiderer, B., Lueken, U., Bruhn, H., Rehbein, H., Fehm, L., Konrad, C., Kircher, T., Reinhardt, I., Wittchen, H.-U. and Ströhle, A. (2010).]

=end of page=